The Podophage PM16 Enhances the Humoral Immune Response Against

Lina Al Allaf, Anton V Chechushkov, Vera V Morozova, Yulia N Kozlova, Tatiana A Ushakova, Nina V Tikunova

Abstract read

In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lina Al AllafLaboratory of Molecular Microbiology, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0003-0981-7722

Anton V ChechushkovLaboratory of Molecular Microbiology, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0002-0238-4533

Vera V MorozovaLaboratory of Molecular Microbiology, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0002-0869-3476

Yulia N KozlovaLaboratory of Molecular Microbiology, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.

Tatiana A UshakovaLaboratory of Molecular Microbiology, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.

Nina V TikunovaLaboratory of Molecular Microbiology, Institute of Chemical Biology and Fundamental Medicine Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia.

Funding

Russian Ministry of Education and Science 125012300671-8Russian Scientific Foundation 25-64-00030

6 · The paper itself

Abstract

Considering the therapeutic potential of the

Indexed as

BacteriophagesImmunity, HumoralProteus InfectionsProteus mirabilisAnimalsAntibodies, BacterialAntibodies, NeutralizingFemaleImmunoglobulin GMiceMice, Inbred BALB CPhage TherapyAntibodies, BacterialAntibodies, NeutralizingImmunoglobulin Gantibiotic resistancebacteriophagehumoral immunityphage therapyPM16Proteus mirabilis

Identifiers

PMID42357678

DOI10.3390/v18060669

PMCPMC13307579

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.